Toru Miyoshi

Toru Miyoshi

M.D.; Ph.D

Cardiologist

22+ years Experience

Male📍 Clayton

About of Toru Miyoshi

Toru Miyoshi is a cardiologist based in Clayton, VIC, working at 246 Clayton Road, Clayton, VIC 3168, Australia. People often visit for heart and blood vessel problems, especially when symptoms like chest pain, breathlessness, or an irregular heartbeat start getting in the way of daily life.


With 22+ years’ experience, Dr Miyoshi looks after both routine and more complex cardiac conditions. In many cases, that includes things like angina, coronary heart disease, and heart attacks. He also helps manage ongoing problems such as high blood pressure, high cholesterol, type 2 diabetes, and atherosclerosis, which can all raise the risk of heart disease over time.


Heart rhythm issues are another big part of his work. Conditions such as atrial fibrillation and other arrhythmias can feel scary and unpredictable. Dr Miyoshi also treats heart failure, including heart failure with preserved ejection fraction (HFpEF). For some people, this means working out the right day-to-day plan so symptoms can be reduced and quality of life can improve.


Some heart concerns involve the valves and the big arteries too. Dr Miyoshi treats problems like valve disease and a range of aortic issues, including aneurysms and dissections. At times, this includes emergencies where prompt assessment and treatment matter. He also works with conditions connected to blood flow, like peripheral artery disease and related circulation concerns.


Procedures and treatment can include options such as percutaneous coronary intervention (PCI) and angioplasty, and for selected cases, more involved treatments like bypass surgery. Depending on the situation, care may also include pacemaker placement, cardiac ablation, and management around acute coronary syndromes. He also has experience across different types of cardiac conditions, from cardiomyopathy to congenital heart disease.


Dr Miyoshi holds an M.D. and a Ph.D. from Okayama University. Research is part of his background, and he has publications listed from his academic work. There aren’t specific clinical trial details shown here, but his training and long career reflect a steady focus on evidence-based heart care.

Education

  • Ph.D.; Okayama University
  • M.D.; Okayama University

Services & Conditions Treated

AnginaCoronary Heart DiseaseStable AnginaAbdominal Aortic Aneurysm (AAA)AtherosclerosisHigh CholesterolPercutaneous Coronary Intervention (PCI)Thoracic Aortic AneurysmAcute Coronary SyndromeAtrial FibrillationCalcinosisCardiomyopathyCoronary Artery SpasmFamilial HypertriglyceridemiaHeart AttackHeart FailureHeart Failure with Preserved Ejection Fraction (HFpEF)HypertensionNon-Alcoholic Fatty Liver DiseaseType 2 Diabetes (T2D)Unstable AnginaVentricular FibrillationAbdominal Obesity Metabolic SyndromeAngioplastyAortic DissectionAortic RegurgitationAortic Valve StenosisArrhythmiasAtrial Septal Defect (ASD)Cardiac AblationCardiac AmyloidosisCardiac ArrestCardiogenic ShockCerebral HypoxiaCongenital Heart Disease (CHD)Coronary Artery AneurysmCoronary Artery FistulaDilated Cardiomyopathy (DCM)Ebstein's AnomalyEndocardial FibroelastosisEndoscopyHeart Bypass SurgeryHeart TumorHypertrophic Cardiomyopathy (HCM)HypothermiaInfant Hearing LossKawasaki DiseaseLow Blood PressureMetabolic SyndromeMitral Valve ProlapseMyocarditisNonsyndromic Hearing LossPacemaker ImplantationParoxysmal Supraventricular Tachycardia (PSVT)Patent Ductus ArteriosusPatent Foramen OvalePeripheral Artery DiseasePrimary AmyloidosisPulmonary AtresiaPulmonary HypertensionSarcoidosisStrokeTeratoma of the MediastinumThrombectomyTricuspid RegurgitationVasoconstrictionVentricular Tachycardia

Publications

5 total
Role of a Bioelectrical Impedance Analysis in Predicting Anemia among Cardiovascular Disease Patients.

Internal medicine (Tokyo, Japan) • March 16, 2025

Tomoaki Nishikawa, Akinori Higaki, Yutaro Okada, Rikako Horie, Yasuhisa Nakao, Tomoki Fujisawa, Shigehiro Miyazaki, Yusuke Akazawa, Toru Miyoshi, Hiroshi Kawakami, Haruhiko Higashi, Shunsuke Tamaki, Kazuhisa Nishimura, Katsuji Inoue, Shuntaro Ikeda, Osamu Yamaguchi

Objective Anemia frequently complicates cardiovascular disease (CVD) and is associated with high mortality rates. A bioelectrical impedance analysis (BIA) is a noninvasive method for measuring human body composition. A direct association between serum hemoglobin (Hb) levels and the extracellular water-to-total body water (ECW/TBW) ratio, as measured by a BIA in patients with diabetes, has been reported. However, the predictive value of the ECW/TBW ratio for detecting anemia in patients with CVD has not been fully elucidated. Methods We conducted a study involving consecutive patients admitted to our cardiology department from January 1, 2021, to December 31, 2022. A BIA was performed once during hospitalization for all patients, whenever possible. The correlation between the Hb level and ECW/TBW ratio was assessed. The predictive accuracy for anemia was evaluated using a receiver operating characteristic (ROC) curve analysis. Results The ECW/TBW ratio was significantly higher in the anemia group than in the non-anemia group (0.41 [0.40, 0.41] vs. 0.39 [0.38, 0.40], p<0.001). The ECW/TBW ratio exhibited a significant negative correlation with Hb, with an R value of 0.57 and a p-value of <0.01. However, this correlation coefficient decreased to 0.45 among subjects with BNP levels ≥200 pg/mL. The area under the ROC curve (AUC) for the ECW/TBW ratio for detecting anemia was 0.83. However, its predictive performance decreased in patients with BNP levels exceeding 200 pg/mL, with an AUC of 0.71. Conclusion The BIA-derived ECW/TBW ratio is a valuable predictor of anemia in patients with CVD, provided BNP levels are not elevated.

Induced Pluripotent Stem Cells in Cardiomyopathy: Advancing Disease Modeling, Therapeutic Development, and Regenerative Therapy.

International Journal Of Molecular Sciences • May 02, 2025

Cardiomyopathies are a heterogeneous group of heart muscle diseases that can lead to heart failure, arrhythmias, and sudden cardiac death. Traditional animal models and in vitro systems have limitations in replicating the complex pathology of human cardiomyopathies. Induced pluripotent stem cells (iPSCs) offer a transformative platform by enabling the generation of patient-specific cardiomyocytes, thus opening new avenues for disease modeling, drug discovery, and regenerative therapy. This process involves reprogramming somatic cells into iPSCs and subsequently differentiating them into functional cardiomyocytes, which can be characterized using techniques such as electrophysiology, contractility assays, and gene expression profiling. iPSC-derived cardiomyocyte (iPSC-CM) platforms are also being explored for drug screening and personalized medicine, including high-throughput testing for cardiotoxicity and the identification of patient-tailored therapies. While iPSC-CMs already serve as valuable models for understanding disease mechanisms and screening drugs, ongoing advances in maturation and bioengineering are bringing iPSC-based therapies closer to clinical application. Furthermore, the integration of multi-omics approaches and artificial intelligence (AI) is enhancing the predictive power of iPSC models. iPSC-based technologies are paving the way for a new era of personalized cardiology, with the potential to revolutionize the management of cardiomyopathies through patient-specific insights and regenerative strategies.

Pathophysiology and management of adults with complex congenital heart disease after biventricular repair.

Journal Of Cardiology • February 14, 2025

Mitsutaka Nakashima, Norihisa Toh, Takashi Miki, Yoichi Takaya, Koji Nakagawa, Kazuhiro Omori, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Morita, Teiji Akagi, Shinsuke Yuasa

Surgical management of congenital heart disease encompasses a spectrum of procedures, ranging from biventricular repair to univentricular palliation, each tailored to the specific anatomical and hemodynamic features of individual cases. Among these, biventricular repair, which preserves a functional ventricle to sustain pulmonary circulation, is prioritized whenever feasible. Advances in approaches have significantly improved outcomes, enabling many patients with congenital heart disease to reach adulthood, including the majority who have undergone biventricular repair. Despite these advancements, long-term complications-such as valvular disease, arrhythmias, heart failure, outflow tract obstruction, and dysfunction of extracardiac conduits-pose persistent challenges in the lifelong care of these patients. This review examines the distinct challenges and management strategies associated with adult patients who have undergone biventricular repair for complex congenital heart disease. The discussion focuses on key conditions, including repaired tetralogy of Fallot, transposition of the great arteries following atrial or arterial switch procedures, surgically managed or untreated congenitally corrected transposition of the great arteries with significant tricuspid regurgitation necessitating intervention, pulmonary atresia with intact ventricular septum, and Ebstein's anomaly. By addressing the long-term complications and therapeutic considerations unique to this patient population, this review aims to provide a comprehensive framework for optimizing care as these individuals transition into adulthood.

Impact of High-Sensitivity Cardiac Troponin T on Clinical Outcomes in Patients With Cardiac Sarcoidosis.

Circulation Journal : Official Journal Of The Japanese Circulation Society • February 09, 2025

Yoichi Takaya, Koji Nakagawa, Toru Miyoshi, Nobuhiro Nishii, Hiroshi Morita, Kazufumi Nakamura, Shinsuke Yuasa

Background: The prognostic utility of high-sensitivity cardiac troponin T (hs-cTnT) on clinical outcomes in cardiac sarcoidosis (CS) remains unknown, so we evaluated hs-cTnT in the chronic phase of CS. Results: We enrolled 92 consecutive patients with CS in the chronic phase after medical therapies. Patients were divided into 2 groups according to hs-cTnT level: 0.014 ng/mL: high hs-cTnT (n=37); normal hs-cTnT (n=55). The primary endpoint was cardiac death and the secondary endpoint was cardiac death, ventricular tachyarrhythmias, or hospitalization for heart failure. The mean age of patients was 63±11 years, and 75 received steroid treatment. During a median follow-up of 63 months, there were 9 cardiac deaths: 7 (19%) patients with high hs-cTnT and 2 (4%) patients with normal hs-cTnT. The rate of cardiac death was higher in patients with high hs-cTnT than in those with normal hs-cTnT (log-rank, P<0.01). Cox proportional hazard analysis showed that hs-cTnT was an independent predictor of cardiac death. The events rate was higher in patients with high hs-cTnT than in those with normal hs-cTnT (log-rank, P<0.01): cardiac death, ventricular tachyarrhythmias or hospitalization for heart failure occurred in 24 (65%) patients with high hs-cTnT and 11 (20%) patients with normal hs-cTnT. Conclusions: Elevated hs-cTnT was linked with adverse outcomes in CS patients, suggesting it is an effective prognostic biomarker.

Aging of the Tricuspid Valvular Annulus detected using photon-counting detector computed tomography.

Heart Rhythm • January 29, 2025

Hiroshi Morita, Koji Nakagawa, Satoshi Nagase, Yoshihisa Morimoto, Takuro Masuda, Akira Ueoka, Saori Asada, Masakazu Miyamoto, Norihisa Toh, Toru Miyoshi, Nobuhiro Nishii, Shinsuke Yuasa

Background: The aortic root (Ao) compresses the heart in elderly patients, potentially influencing the conduction system and causing atrial tachyarrhythmias (ATAs). However, actual anatomical alterations in the right side of the heart because of Ao compression have not yet been fully evaluated. Objective: This study aimed to elucidate the alterations in the tricuspid valvular annulus (TVA) caused by Ao compression using a 3-dimensional endoscopic view of the heart constructed by photon-counting detector computed tomography (PCD-CT), an emerging medical technology. Methods: We analyzed 135 consecutive patients who underwent PCD-CT at our institute after excluding those with diseases that directly influenced the right heart. Results: Ao-compression caused significant TVA deformation. We defined severe TVA compression as the length of the TVA compressed by the aortic root ≥80% of the major axis of the TVA. Severe compression was more prevalent in elderly patients (age ≥ 75 years, 42%; p<0.01). The distance between the membranous septum and ostium of the coronary sinus was shortened, whereas the cavotricuspid isthmus (CTI) was elongated in older patients. The regression analysis identified aging as a significant contributor to TVA compression. The short minor and long major axes of the TVA, incidence of ATAs (70% vs. 45%, p<0.01), and atrioventricular conduction disturbances (38% vs. 15%, p<0.01) were more frequently observed in patients with severe compression. Conclusions: Ao-compression deforms the TVA and alters the anatomical relationship between the atrioventricular conduction system and the CTI. Therefore, Ao-compression may contribute to the occurrence of ATAs and conduction disturbances in older patients.

Frequently Asked Questions

What conditions does Dr Toru Miyoshi treat?
Dr Miyoshi treats a wide range of heart and blood vessel conditions, including angina, coronary heart disease, atrial fibrillation, heart failure, hypertension, arrhythmias, aortic disease, valve problems, and metabolic conditions linked to heart health.
What services does he offer?
He provides many cardiology services such as angioplasty (PCI), cardiac ablation, evaluation and management of acute coronary syndrome, heart rhythm problems, heart failure, and imaging and treatment for aortic and valve issues.
Where is the clinic located?
The clinic is at 246 Clayton Road, Clayton, VIC 3168, Australia.
How can I arrange an appointment?
To book an appointment, contact the Clayton clinic directly. You may be advised on suitable times based on availability and your medical needs.
What should I bring to my appointment?
Bring any relevant medical records, current medications, and details of your symptoms or prior heart tests to help with your assessment.
What is Dr Miyoshi’s background?
Dr Miyoshi holds an MD and PhD with over 22 years of experience in cardiology.

Contact Information

246 Clayton Road, Clayton, VIC 3168, Australia

Is this your profile?

Claim this profile →

Memberships

  • Fellow of Japanese Circulation Society
  • Japan Vascular Failure Society
  • Japanese Society of Hypertension
  • Japanese Society of Cardiovascular Imaging and Dynamics